Elizabeth Warren wants Gilead CEO Daniel O'Day in the hot seat to talk drug pricing and competitiveness
Given Gilead’s experience in developing storied new drugs for hepatitis C and Covid-19, and marketing them with hefty price tags, Massachusetts Sen. Elizabeth Warren (D) sent a letter on Friday to CEO Daniel O’Day, calling on him to testify before a subcommittee of the Senate Finance Committee on “Promoting Domestic Competition and International Competitiveness.”
While noting that “the prohibitively high prices of Gilead’s drugs have made it hard for patients to access the lifesaving treatments they need, forced taxpayers to bear the brunt of high costs, and inhibited competition,” Warren said she’s offering O’Day “an opportunity to offer context on pharmaceutical competition and the burden of high drug prices on patients and the American public.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.